Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the ...

A new study from Queen Mary University of London found that 9% of all reported adverse drug reactions (ADRs) reported to the UK medicines regulator are associated with medications where side effect ...

The integration of AI and cloud technologies is transforming pharmaceutical manufacturing regulations, focusing on safety, efficiency, and global harmonization.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) ...

While early steps have been taken in Austria and France, Belgium MEP Yvan Verougstraete stresses the need for a long-term ...

Shanghai Henlius Biotech, Inc. (2696) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has valida ...

A landmark study looking at all adverse drug reactions ever recorded in Britain since 1964 reveals just three genes could be ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

The European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment ...